The effect of lutein supplementation on macular pigment density in patients who have undergone cataract surgery

ISRCTN ISRCTN71306406
DOI https://doi.org/10.1186/ISRCTN71306406
Secondary identifying numbers #462
Submission date
04/11/2009
Registration date
25/11/2009
Last edited
25/11/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Catherine Creuzot-Garcher
Scientific

Hopital Général Service d'ophtalmologie
3 rue de Faubourg Raines
Dijon Cedex
BP151921034
France

Study information

Study designProspective open monocentric non-controlled pilot study
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleProspective, open, pilot study of oral supplementation with lutein in patients having undergone cataract surgery: effect on macular pigment density
Study acronymLutein Pilot Study
Study objectivesIn this study will be tested the hypothesis that a 6 month treatment, after cataract surgery, of lutein at a dosage of 10 mg daily, significantly increases macular pigment optical density as measured by a Raman spectrometer. The null hypothesis, expected to be rejected, is that there is no difference between the measurement just after surgery and the measurement 6 months after surgery. An additional hypothesis, that a 2 month treatment of lutein increases macular pigment optical density before cataract surgery, will also be tested.
Ethics approval(s)Local medical ethics committee (Comite consultatif de protection des personnes dans la recherche biomedicale de Bourgogne) approved on the 9th May 2006
Health condition(s) or problem(s) studiedCataract
InterventionThis was an open-label pilot study at a single site to assess if eight months of lutein supplementation results in a significant increase in macular pigment optical density and plasma lutein levels to protect the macula of subjects after cataract surgery.

There was no control group in this study.

A total of at least 40 subjects were planned for enrolment in this single site study. All included subjects received 10 mg soft capsules of lutein (containing lutein and vitamin E). Each subject was to swallow one capsule daily with a glass of water without chewing. The planned treatment duration was eight months.

Cataract surgery was to be scheduled two months after enrolment. One week after surgery, data was to be collected to establish baseline information for post-surgery MPOD.

A follow-up visit was planned for two months (+/- 7 days) following surgery and the final follow-up visit was planned for six months (+/- 2 weeks) after surgery.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Lutein
Primary outcome measureTo check that lutein supplementation of 10 mg results in significant Macular pigment optical density (MPOD) increase to protect the macula of patients after cataract surgery and significant increase in lutein plasma levels
Secondary outcome measures1. Macular pigment optical density increase after lutein supplementation before surgery to protect the macula during surgery
2. Plasma levels of lutein to check treatment compliance
3. Safety of oral lutein supplementation
Overall study start date05/07/2006
Completion date24/10/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsAt least 40
Key inclusion criteria1. Men or women aged over 55 years
2. Having to undergo cataract surgery on one eye (study eye) with extracapsular cataract extraction (ECCE) by phacoemulsification and insertion of a posterior chamber implant
3. Written informed consent
Key exclusion criteria1. Body mass index (BMI) greater than or equal to 29 kg/m^2
2. Poor pupillary dilation less than 6 mm with mydriatic drugs
3. Age-related maculopathy or macular degeneration (Age-Related Eye Disease Study [AREDS] class 2, 3 or 4)
4. Diabetic retinopathy
5. History of other progressive disease in the study eye which may complicate the assessment of pigment density
6. Known sensitivity to lutein, vitamin E or vehicules
7. Use of cholesterol-lowering drugs that act as bile acid binders (may interfere with carotenoid absorption) within the last month
8. Concomitant disease or therapy which could interfere with lutein absorption
9. Supplementation with carotenoids within the previous 6 months
10. Drastic change of food and/or food supplements within the last month
11. Involvement in the last 30 days in any investigational drug study
Date of first enrolment05/07/2006
Date of final enrolment24/10/2008

Locations

Countries of recruitment

  • France

Study participating centre

Hopital Général Service d'ophtalmologie
Dijon Cedex
BP151921034
France

Sponsor information

Dr. Mann Pharma GmbH, Bausch & Lomb Group (Germany)
Industry

Brunsbütteler Damm 165 - 173
Berlin
13581
Germany

Website http://www.bausch-lomb.de/
ROR logo "ROR" https://ror.org/049ncrn81

Funders

Funder type

Industry

Dr. Mann Pharma GmbH, Bausch & Lomb Group (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan